Vivek Subbiah: News article on the AACR Plenary Session 2024

Vivek Subbiah shared on LinkedIn:

“News article on the AACR Plenary Session 2024

‘AI at the Interface: Accelerating Evidence Generation, Advancing Disparities Research, and Improving Trial Design’
So delighted to Chair the Plenary on AI.
‘This plenary session not only sheds light on the incredible strides we’ve made but also opens doors to future transformative research in this critical intersection,’ he said. ‘As we navigate the intricate realms of artificial intelligence and oncological advancements, this session serves as a beacon, guiding us toward unparalleled breakthroughs and pioneering solutions for the challenges that lie ahead.'”

View additional information.
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.